I stand corrected on Peds - not part of Aug. PDUFA date.
On labeling negotiations - My question is why did Talon dose first patient post May PDUFA extension and why is the confirmatory study powered for superiority?
Trust me, any drug company with a pending drug under FDA review & pre-approval cannot give specifics. Labeling negotiations is even more that I think is appropriate, but no one besides the FDA & Talon knows what that means. Coould be dose related, indications, post marketing...